Search - tctmd.com

Displaying 81 - 100 of 101

Sort: Relevancy | Date

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2016

Older Men With Existing Coronary Disease at Highest Risk of Dying During a Triathlon

Michael O'Riordan

April 06, 2016

News Conference News ACC 2016

Watchman Left Atrial Appendage Closure Device Fares Well in Early Commercial Experience

Todd Neale

April 03, 2016

News Conference News ACC 2016

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

Shelley Wood

April 03, 2016

Presentation ACC 2016

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Presenter: Vinod Thourani

April 01, 2016

News Conference News ACC 2015

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

L.A. McKeown

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Study Looks at Long-term Mortality Predictors in TAVR Patients

Jason Kahn

March 27, 2012

Presentation ACC 2012

Late (≥ 2 year) Clinical and Echocardiographic Outcomes after Transcatheter vs. Surgical Aortic Valve Replacement: Results from the High-Risk Cohort of The PARTNER Trial

Presenter: Susheel K. Kodali

March 26, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Advertisement

Live From Washington: ACC 2017, Day Three

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Live From Washington: ACC 2017, Day Two

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Older Men With Existing Coronary Disease at Highest Risk of Dying During a Triathlon

Watchman Left Atrial Appendage Closure Device Fares Well in Early Commercial Experience

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Study Looks at Long-term Mortality Predictors in TAVR Patients

Late (≥ 2 year) Clinical and Echocardiographic Outcomes after Transcatheter vs. Surgical Aortic Valve Replacement: Results from the High-Risk Cohort of The PARTNER Trial

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content